Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19
Abstract The severe respiratory insufficiency observed during COVID-19 infection may not be directly related to a cytopathogenic effect induced by the virus itself, but to an exaggerated and inappropriate immune response. In an effort to reduce the severity of organ dysfunction, including respirator...
Main Authors: | Joseph Meletiadis, Sotirios Tsiodras, Panagiotis Tsirigotis |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-08-01
|
Series: | Infectious Diseases and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40121-020-00326-1 |
Similar Items
-
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
by: Camille Keenan, et al.
Published: (2021-02-01) -
The Many Faces of JAKs and STATs Within the COVID-19 Storm
by: Alice H. Grant, et al.
Published: (2021-07-01) -
Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma
by: Juliane Lokau, et al.
Published: (2019-11-01) -
Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11
by: Riley D. Metcalfe, et al.
Published: (2020-07-01) -
JAK/STAT as a Potential Therapeutic Target for Osteolytic Diseases
by: Mariely A. Godoi, et al.
Published: (2023-06-01)